UCI Chemistry’s Professor Sarah Finkeldei, as part of a collaboration with Serva Energy, ASU, and the Mayo Clinic, is working to provide new synthetic pathways to medical isotopes for application in Targeted Alpha Therapies for cancer treatment. Using UCI’s nuclear reactor, they have transformed Radium-226, a nuclear waste product, to Actinium-225.